4 March
2024
VALIRX PLC
("ValiRx" or the
"Company")
Shareholder Requisition
Notice
ValiRx plc (the "Company") (AIM:
VAL), a life sciences company focusing on early-stage cancer
therapeutics and women's health, announces that it has received a
requisition from shareholders representing over 7% of the Company's
voting rights to convene a General Meeting ("GM") of the Company
(the "Requisition") under section 303 of the Companies Act 2006
(the "Act"). The Requisition requests for the following Ordinary
Resolutions to be proposed at the General Meeting:
1. That
Martin Lampshire be removed from the board of directors of the
Company with immediate effect.
2. That
Kevin Cox be removed from the board of directors of the Company
with immediate effect.
3. That
Adrian De Courcey be appointed as a non-executive director of the
Company with immediate effect.
4. That
Benjamin Snipe be appointed as a non-executive director of the
Company with immediate effect.
5. That Ray
Horn be appointed as Board Observer of the Company with immediate
effect.
6. That,
subject to the passing of resolution 2, a) an interim Chairperson
be appointed to the Board of the Company; and b) Shard Capital, the
Company's broker, be requested by the Board to provide at least one
candidate for the permanent role of non-executive Chairperson by 31
May 2024; if at least one candidate is provided to the Board, the
Board may decide to appoint to the role accordingly, but is not
required to; otherwise the Board is to proceed with recruitment to
the role using services of an external recruitment
agency.
7. That any
person appointed as a director of the Company since the date of the
requisition of the general meeting of the Company at which this
resolution is proposed, and who is not one of the persons referred
to in the resolutions numbered 3 and 4 above, be and is hereby
removed as a director of the Company.
A further announcement will be made
by the Company relating to the calling of a General Meeting and a
Notice of General Meeting and accompanying circular will posted to
shareholders.
Pursuant to section 304 of the
Companies Act 2006, the Company must post a notice convening a
general meeting within 21 days from the date on which the
requisition was received, and this meeting must be held on a date
not more than 28 days after the date of the notice to shareholders
convening the general meeting.
The information contained within
this announcement is deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulations (EU)
No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR").
The Directors of the Company take
responsibility for this announcement.
For more information, please
contact:
ValiRx plc
Dr Suzanne Dilly, CEO
|
Tel: +44 (0) 2476 796496
www.valirx.com
Suzanne.Dilly@valirx.com
|
V
Formation (Public Relations)
Lucy Wharton - Senior PR
Executive
Sue Carr - Director
|
+44
(0) 115 787 0206
www.vformation.biz
lucy@vformation.biz
sue@vformation.biz
|
Cairn Financial Advisers LLP (Nominated
Adviser)
Liam Murray/Jo Turner/Ludovico
Lazzaretti
|
Tel: +44 (0) 20 7213 0880
|
Shard Capital Partners LLP (Sole Broker)
Damon Heath
|
Tel: +44 (0) 20 7186 9000
|
Notes for Editors
About ValiRx
ValiRx is a life science company
focused on early-stage cancer therapeutics and women's health,
accelerating the translation of innovative science into impactful
medicines to improve patient lives.
ValiRx provides the scientific,
financial, and commercial framework for enabling rapid translation
of innovative science into clinical development.
Using its extensive and proven
experience in research and drug development, the team at ValiRx
selects and incubates promising novel drug candidates and guides
them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines
across scientific, technical, and commercial domains, with the aim
of achieving a more streamlined, less costly, drug development
process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for
science to advance.
Lead candidates from ValiRx's
portfolio are outlicensed or partnered with investors through
ValiRx subsidiary companies for further clinical development and
commercialisation.
ValiRx listed on the AIM Market of
the London Stock Exchange in October 2006 and trades under the
ticker symbol: VAL.
For further information,
visit: www.valirx.com
Cautionary statement
Certain statements made in this
announcement are forward-looking statements. Such statements are
based on current expectations and assumptions and are subject to a
number of risks and uncertainties that could cause actual events or
results to differ materially from any expected future events or
results expressed or implied in these forward-looking statements.
Persons receiving this announcement should not place undue reliance
on forward-looking statements. Unless otherwise required by
applicable law, regulation or accounting standard, the Company does
not undertake to update or revise any forward-looking statements,
whether as a result of new information, future developments or
otherwise.